Exposure to bug or weed killers is associated with higher risk of Parkinson's disease

A large analysis of more than 100 studies from around the world shows that exposure to pesticides, or bug and weed killers, and solvents is likely associated with a higher risk of developing Parkinson's disease. The research appears in the May 28, 2013, print issue of Neurology-, the medical journal of the American Academy of Neurology.

"Due to this association, there was also a link between farming or country living and developing Parkinson's in some of the studies," said study author Emanuele Cereda, MD, PhD, with the IRCCS University Hospital San Matteo Foundation in Pavia, Italy. The research was also conducted by Gianni Pezzoli, MD, with the Parkinson Institute - ICP, Milan.

For the analysis, researchers reviewed 104 studies that looked at exposure to weed, fungus, rodent or bug killers, and solvents and the risk of developing Parkinson's disease. Studies that evaluated the proximity of exposure, such as country living, work occupation and well water drinking were also included.

The research found that exposure to bug or weed killers and solvents increased the risk of developing Parkinson's disease by 33 to 80 percent. In controlled studies, exposure to the weed killer paraquat or the fungicides maneb and mancozeb was associated with two times the risk of developing the disease.

"We didn't study whether the type of exposure, such as whether the compound was inhaled or absorbed through the skin and the method of application, such as spraying or mixing, affected Parkinson's risk," said Cereda. "However, our study suggests that the risk increases in a dose response manner as the length of exposure to these chemicals increases."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Researchers use cerebrospinal fluid to unlock pathways in Alzheimer's disease